Hongzhou Lu

Prof. Hongzhou Lu is a leading scientist of internal medicine. He has engaged in the research, education and clinical practice for the infectious diseases, particularly for the functional cure of AIDs since 1988. His working fields include as follws: fever of unknown origin; rational use of antibiotics; infection of the central nervous system; infection of the respiratory system. He finished his undergraduate course in clinical medicine at Bengbu Medical College, and became a M.D. of internal medicine (1988). He obtained his Ph.D degree in internal medicine at Shanghai Medical University (1999), and finished his postdoctoral training at Vanderbilt University Medical Center, TN, USA (2002). After he finished his resident training, he joined the Huashan Hospital of Fudan University, and served as a doctor-in-charge at that hospital. From 2002, after finished his postdoctoral training, he was appointed his first professorship in lemology at Huashan Hospital of Fudan University. From 2012, he relocated to the Shanghai Public Health Clinical Center Affiliated to Fudan University, and became a full professor in lemology as well the director/leader of that hospital till 2021. Then he moved to Shenzhen Third People’s Hospital, Second Hospital Affiliated to Southern University of Science and Technology (SUSTech), National Clinical Research Center for Infectious Diseases. Now he is serving as a full professor in lemology of SUSTech as well as the director/leader of this hospital. He founded an international academic journal iLABMED, and became the Editor-in-Chief in 2023. From 2024, he was selected as the deputy dean of Medical School of SUSTech. He is also serving as a Ph.D/master mentor in Fudan University, SUSTech, and Bengbu Medical University.

Prof. Lu is a distinguished researcher in his fields. He has got over 500 peer-reviewed scientific publications as the first/corresponding author, including the world’s top journals such as NEJM, Nature, and STTT. He published 15 scientific books and obtained 15 patents. He was included as the Stanford University's World's Top 2% Scientists in 2021─2024. He was selected as the top 0.05% highly ranked scholar in both lifetime and prior five years by ScholarGPS (https://scholargps.com/).

As a leading clinician in infectious diseases, Prof. Lu makes outstanding contributions in prevention/control of emerging infectious diseases. He was invited as the member of the national committee of experts in prevention/control of COVID-19, as well as the leader of the committee of experts in Shanghai and Shenzhen. He organized and published many guidelines/ expert consensus against emerging infectious diseases such as COVID-19 and Mpox. He also engaged in research & development of many indigenous innovative drugs, such as oral small-molecule drugs in treating COVID-19, including simnotrelvir and SHEN26 capsule, which efficacy and safety have been strictly verified.

Prof. Lu is an experienced international scientist who is keen on international communication and international cooperation. He has rich experience in carrying out international cooperative research. As a leading expert of China CDC, he was invited to The Republic of Sierra Leone to help this country to fight against Ebola virus in 2014. His enthusiastic service and excellent medical skill were highly praised and respected by the local people in Africa. He has succeeded in carrying out many international cooperative projects. Now he is serving as a co-director of WHO Collaborating Centre for Clinical Management and an expert of WHO Clinical Expert Group.